Literature DB >> 29523291

ERCP induced and non-ERCP-induced acute pancreatitis: Two distinct clinical entities?

Ivana Zitinic1, Ivana Plavsic2, Goran Poropat3, Goran Hauser4.   

Abstract

Acute pancreatitis (AP) is a common gastrointestinal disease of varied etiology; however, the most common causes of AP are gallstones and alcohol abuse. AP has emerged as the most frequent complication after endoscopic retrograde cholangiopancreatography (ERCP). Post-ERCP pancreatitis is generally a clinically irrelevant condition; however, it can be severe or even fatal in up to 0.8% of cases. Different clinical courses and outcomes have been observed between mild and severe AP of different etiologies (i.e., non-ERCP AP and post-ERCP AP), which opens the discussion as to whether they are the same or distinct clinical entities.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29523291     DOI: 10.1016/j.mehy.2018.02.017

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  3 in total

Review 1.  Endoscopic Retrograde Cholangiopancreatography-Related Complications and Their Management Strategies: A "Scoping" Literature Review.

Authors:  Kemmian D Johnson; Abhilash Perisetti; Benjamin Tharian; Ragesh Thandassery; Priya Jamidar; Hemant Goyal; Sumant Inamdar
Journal:  Dig Dis Sci       Date:  2019-12-02       Impact factor: 3.199

Review 2.  Endoscopic retrograde cholangiopancreatography-induced and non-endoscopic retrograde cholangiopancreatography-induced acute pancreatitis: Two distinct clinical and immunological entities?

Authors:  Ivana Plavsic; Ivana Žitinić; Ivana Mikolasevic; Goran Poropat; Goran Hauser
Journal:  World J Gastrointest Endosc       Date:  2018-10-16

3.  Recurrence and survival after surgery for pancreatic cancer with or without acute pancreatitis.

Authors:  Qian Feng; Cheng Li; Sheng Zhang; Chun-Lu Tan; Gang Mai; Xu-Bao Liu; Yong-Hua Chen
Journal:  World J Gastroenterol       Date:  2019-10-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.